In a small, proof of concept randomized controlled trial, lucagliflozin, a selective and potent dual SGLT1/SGLT2 inhibitor, demonstrated significant weight loss (5.7%) versus placebo (p < .001) in patients with obesity, and favourable increases in incretin hormones and urinary glucose excretion (∼100 g) in patients with T2D [77]. Here, GCG is linked to type 2 diabetes mellitus.